Rapid generation of circulating and mucosal decoy human ACE2 using mRNA nanotherapeutics for the potential treatment of SARS‐CoV‐2
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) can cause lethal
pulmonary damage in humans. It contains spike proteins on its envelope that bind to human …
pulmonary damage in humans. It contains spike proteins on its envelope that bind to human …
Rapid generation of circulating and mucosal decoy ACE2 using mRNA nanotherapeutics for the potential treatment of SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters through the airways
and infects the lungs, causing lethal pulmonary damage in vulnerable patients. This virus …
and infects the lungs, causing lethal pulmonary damage in vulnerable patients. This virus …
Secreted expression of mRNA‐encoded truncated ACE2 variants for SARS‐CoV‐2 via lipid‐like nanoassemblies
M Li, S Li, Y Huang, H Chen, S Zhang… - Advanced …, 2021 - Wiley Online Library
The transfer of foreign synthetic messenger RNA (mRNA) into cells is essential for mRNA‐
based protein‐replacement therapies. Prophylactic mRNA COVID‐19 vaccines commonly …
based protein‐replacement therapies. Prophylactic mRNA COVID‐19 vaccines commonly …
An intranasal ASO therapeutic targeting SARS-CoV-2
The COVID-19 pandemic is exacting an increasing toll worldwide, with new SARS-CoV-2
variants emerging that exhibit higher infectivity rates and that may partially evade vaccine …
variants emerging that exhibit higher infectivity rates and that may partially evade vaccine …
A simplified SARS-CoV-2 mouse model demonstrates protection by an oral replicon-based mRNA vaccine
A mouse model of SARS-CoV-2 that can be developed in any molecular biology lab with
standard facilities will be valuable in evaluating drugs and vaccines. Here we present a …
standard facilities will be valuable in evaluating drugs and vaccines. Here we present a …
Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung injury in a non-human primate model of COVID-19
Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has grown into a global pandemic, and only a few …
syndrome coronavirus 2 (SARS-CoV-2), has grown into a global pandemic, and only a few …
[HTML][HTML] Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2
We have previously provided the first genetic evidence that angiotensin converting enzyme
2 (ACE2) is the critical receptor for severe acute respiratory syndrome coronavirus (SARS …
2 (ACE2) is the critical receptor for severe acute respiratory syndrome coronavirus (SARS …
Engineered trimeric ACE2 binds viral spike protein and locks it in “Three-up” conformation to potently inhibit SARS-CoV-2 infection
Dear Editor, Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in a severe global pandemic. Following …
syndrome coronavirus 2 (SARS-CoV-2) has resulted in a severe global pandemic. Following …
Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov
Abstract A novel coronavirus (2019-nCov) was identified in Wuhan, Hubei Province, China
in December of 2019. This new coronavirus has resulted in thousands of cases of lethal …
in December of 2019. This new coronavirus has resulted in thousands of cases of lethal …
[PDF][PDF] Single-cell RNA expression profiling shows that ACE2, the putative receptor of Wuhan 2019-nCoV, has significant expression in the nasal, mouth, lung and …
C Wu, M Zheng - 2020 - preprints.org
Abstract A novel coronavirus (2019-nCoV) was first identified in Wuhan, Hubei Province,
and then spreads to the other Provinces of China. 2019-nCoV was reported to share the …
and then spreads to the other Provinces of China. 2019-nCoV was reported to share the …